Matthew Galsky, MD, professor of Medicine, Mount Sinai School of Medicine, discusses the significant findings in, and the rationale behind conducting the CheckMate-275 trial during an interview at the 2016 ESMO Congress.
PROs Strengthen Case for Mirvetuximab Soravtansine as SOC in FRα+ Ovarian Cancer
March 16th 2024Patient reported health-related quality of life outcomes from the phase 3 MIRASOL trial strengthen the case for mirvetuximab soravtansine as a new standard of care for patients with folate receptor-alpha positive ovarian cancer resistant to platinum chemotherapy.
Read More